-
Product Insights
NewHuman Immunodeficiency Virus (HIV) Tests Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
HIV Tests Pipeline Market Report Overview Human Immunodeficiency Virus (HIV) tests refer to the antigens, antibodies, and nucleic acid reagent tests performed for the detection of HIV type I. The HIV Tests pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Laquinimod Sodium in Non-infectious Uveitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Laquinimod Sodium in Non-infectious Uveitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Laquinimod Sodium in Non-infectious Uveitis Drug Details: Laquinimod sodium (ABR-215062) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acalabrutinib Maleate in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acalabrutinib Maleate in Graft Versus Host Disease (GVHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acalabrutinib Maleate in Graft Versus Host Disease (GVHD)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Melanoma Drug Details: RP-1 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BDB-001 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BDB-001 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BDB-001 in Transitional Cell Carcinoma (Urothelial Cell...
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2023’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Non-infectious Uveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-infectious Uveitis - Drugs In Development, 2023’, provides an overview of the Non-infectious Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-infectious Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Myelofibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myelofibrosis - Drugs In Development, 2023’, provides an overview of the Myelofibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Uveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Uveitis - Drugs In Development, 2023’, provides an overview of the Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Influenzavirus B Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenzavirus B Infections - Drugs In Development, 2023’, provides an overview of the Influenzavirus B Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenzavirus B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...